Biopsychosocial Risk Factors, Stigma, Treatments, Happiness, Motivation, and Flow
Biopsychosocial Framework and Risk Factors for Psychological Disorders
The Biopsychosocial Model:
Mental health is affected by a complex interaction of biological, psychological, and social factors.
Every individual is unique; interventions that work for one person may not work for another.
Biological Domain: Biological physical health, disabilities, genetic predispositions, neurochemistry, immune response, drug effects, temperament.
Psychological Domain: Beliefs, behavior, personality, self-esteem, coping skills, emotions, social skills, rumination, reasoning and memory processes, stress responses.
Social and Environmental Domain: Peer relationships, family circumstances, cultural traditions, social support, education, poverty, life events, environmental exposures.
Risk Factors vs. Protective Factors:
Risk Factors: Attributes, conditions, or exposures that increase the likelihood of an individual developing a psychological disorder or experiencing a relapse of an existing condition. Psychological disorders are rarely caused by a single isolated risk factor; rather, multiple and persistent risk factors interact over time.
Protective Factors: Attributes or environmental resources that guard against the onset or relapse of psychological disorders by supporting general wellbeing, fostering resilience in the face of adversity, and softening the physiological and psychological impact of stress.
Systemic Classification of Factors Affecting Mental Health:
Individual Attributes Level:
Risk Factors: Low self-esteem, cognitive or emotional immaturity, difficulties in communicating, medical illness, substance use.
Protective Factors: Self-esteem, confidence, ability to solve problems and manage stress or adversity, communication skills, physical health, physical fitness.
Environmental Factors Level:
Risk Factors: Poor access to basic services, injustice and discrimination, social and gender inequalities, exposure to war or disaster.
Protective Factors: Equality of access to basic services, social justice, tolerance, integration, social and gender equality, physical security and safety.
Social Circumstances Level:
Risk Factors: Loneliness, bereavement, neglect, family conflict, exposure to violence or abuse, low income and poverty, difficulties or failure at school, work stress, unemployment.
Protective Factors: Social support of family and friends, good parenting and healthy family interaction, physical security and safety, economic security, scholastic achievement, satisfaction and success at work.
The 4 P's Model of Risk Factors:
Predisposing Risk Factors: Factors that increase an individual's vulnerability to developing a psychological disorder. These typically account for internal traits, genetic endowments, or biological attributes present from birth or early development.
Precipitating Risk Factors: Specific events or immediate triggers that contribute to the onset of current symptoms, helping clinicians understand why the disorder emerged at a particular point in time. Examples include stressful life situations (financial or legal problems, divorce, death of a loved one, witnessing parental violence), experiencing parental emotional/physical/sexual abuse or neglect, belonging to a marginalized ethnic minority, acute traumatic experiences (assault, military combat, exposure to war/terrorism), and long-term use of specific medications.
Perpetuating Risk Factors: Factors that inhibit recovery and maintain or prolong the duration of a psychological disorder. Examples include ongoing problems with alcohol, tobacco, and drugs; social isolation (having few friends or healthy relationships); persistent relationship difficulties; family conflicts; poverty and homelessness; chronic physical medical conditions (such as heart disease); weakened immune system function; poor parental attachment; history of previous mental illness; missing school or work; and engagement in harm to self or others.
Protective Risk Factors: Factors that reduce the impact of stress and prevent the initial occurrence or recurrence of a psychological disorder by leveraging personal strengths, coping mechanisms, and social supports. Examples include maintaining a good diet, maintaining physical fitness and health, adhering to good sleep hygiene, possessing the ability to recognize early warning signs of relapse, maintaining awareness of potential risk factors, adhering to prescribed medications when relevant, staying connected with family and friends, cultivating awareness and acceptance of the disorder, joining a support group, learning about psychological disorders, anticipating and planning for potential relapse scenarios, avoiding harmful substance use, participating in education/art/engaging activities, maintaining economic wellbeing and reliable employment, and having stable housing.
Biological Risk Factors:
Genetics and Inherited Traits:
Familial, twin, and adoption studies indicate that genetic heritage influences vulnerability to psychological disorders. Genes govern neurodevelopment, brain structure, and baseline neurotransmitter regulation.
Genetic Predisposition: Vulnerability does not guarantee disorder expression; it alters susceptibility thresholds when interacting with environmental stressors.
Schizophrenia Research Evidence: Schizophrenia exhibits a significant genetic component. Heston (1966) investigated infants born to mothers with schizophrenia who were separated at birth and raised by adoptive parents, comparing them to control adopted infants whose biological mothers had no psychiatric diagnosis. Results revealed that of children born to mothers with schizophrenia developed the condition, whereas of the control group developed schizophrenia. A parallel adoption study conducted in Finland established that the risk of developing schizophrenia was if a biological parent was diagnosed, compared to in individuals without a parental diagnosis. The famous Genain quadruplets all developed schizophrenia in their 20s; given their shared genetic profile and family history of psychological disorders, genetic inheritance played a central role in their shared diagnosis.
Pharmacgenomics and Pharmacokinetics (5-Stage Drug Response Process):
Genetic variation governs how individuals metabolize and respond to psychotropic medications across five distinct stages:
Absorption: The process by which the drug enters the systemic bloodstream.
Distribution: The mechanism by which the body transports the drug to its target tissue. For antidepressants, the target site comprises neural pathways within the central nervous system.
Target Interaction: The molecular binding of the drug to target cells. For instance, antidepressants bind to neuronal receptors to inhibit the re-uptake of monoamine neurotransmitters such as serotonin.
Metabolic Processing: Chemical alteration of the drug molecule by enzyme systems (primarily in the liver, but also occurring in the stomach or blood plasma) to enable therapeutic utilization or clear the compound.
Excretion: The physiological removal of metabolic waste products and remaining chemical compounds from the body.
Poor Sleep:
Chronic sleep disturbances are bidirectionally linked with psychological disorders, particularly anxiety, major depressive disorder, bipolar disorder, and attention deficit hyperactivity disorder (ADHD).
Sleep disruption impairs emotional regulation circuits, elevating vulnerability to affective disorders. When evaluating patients, clinicians must determine whether sleep pathology acts as a predisposing/precipitating risk factor or emerges as a perpetuating symptom. Note that while pharmacological agents such as benzodiazepines may manage acute insomnia, long-term administration can exacerbate underlying psychological conditions.
Long-Term Substance Abuse and Neurochemistry:
Chronic substance abuse alters neural circuitry and neurotransmitter pathways, particularly mesolimbic dopamine pathways governing motivation and reward.
Substance-induced neuroadaptations lead to impaired cognitive processing, memory deficits, altered appetite, and sleep disruption. Chronic alcohol use is correlated with depression; cannabis use with depressive disorders; and amphetamine misuse with acute paranoia and severe anxiety.
Dopamine Dynamics: Consumption of addictive substances causes an acute dopamine spike above baseline, followed by a severe crash and prolonged dopamine deficit before gradually returning to baseline. During the deficit phase, individuals experience heightened dysphoria, craving, and vulnerability to relapse.
Psychological Risk Factors:
Rumination:
Definition: The repetitive, passive, and repetitive focusing of attention on the causes, meanings, and consequences of one's distress or negative life events without engaging in active problem-solving.
Unbroken ruminative cycles reinforce maladaptive neural networks, strengthening associative links between negative memories and emotions. Rumination is a core cognitive risk factor maintaining clinical depression and anxiety disorders. Cognitive Behavioral Therapy (CBT) effectively targets rumination by training individuals to reframe and cognitive-reappraise automatic negative thoughts.
Impaired Reasoning and Memory:
Impaired Reasoning: The inability to engage in goal-directed, logical thinking or evaluate evidence objectively. Individuals with reasoning impairments frequently display a "jumping to conclusions" cognitive bias, formulating firm beliefs (delusions) based on inadequate or non-representative evidence. Approximately of individuals diagnosed with schizophrenia exhibit severe reasoning and cognitive impairments.
Impaired Memory: Deficits affecting working memory, short-term memory, or long-term episodic memory storage and retrieval. Commonly observed across schizophrenia, Autism Spectrum Disorder (ASD), major depression, neurocognitive disorders (dementia), Post-Traumatic Stress Disorder (PTSD), and bipolar disorder. Disruptions in memory compromise daily execution, occupational functioning, and interpersonal stability.
Stress and Endocrine Dysfunction:
Acute stress triggers the activation of the sympathetic nervous system and the hypothalamic-pituitary-adrenal (HPA) axis, inducing systemic release of catecholamines (adrenaline) and glucocorticoids (cortisol).
Prolonged, unmanaged stress leads to sustained hypercortisolemia. Hypercortisolemia induces neurotoxic effects on hippocampal structures, impairing synaptic plasticity, memory formation, and emotional regulation. Elevated cortisol is linked to the precipitation of schizophrenia, major depression, and substance use disorders.
Social Risk Factors:
Disorganised Attachment:
An insecure attachment style formed in infancy characterized by inconsistent, contradictory, or apprehensive behavior toward primary caregivers (e.g., approaching a caregiver while avoiding eye contact or freezing). It arises when the caregiver serves as a source of fear rather than safety.
Infants demonstrating disorganized attachment at \,months exhibit heightened rates of disruptive, aggressive, and dysregulated behaviors throughout childhood and adolescence. In adulthood, disorganized attachment impairs emotional self-regulation, reduces stress tolerance, and precipitates interpersonal conflict or hostile behavior, perpetuating risk across generations.
Loss of Significant Relationships:
Significant relationships represent high-importance social bonds characterized by deep affection, attachment, and mutual trust (e.g., romantic partners, family, close friends).
The dissolution or loss of a significant relationship removes critical buffers of social support, significantly increasing vulnerability to major depressive disorder and generalized anxiety.
Grief and Complicated Bereavement Disorder:
Grief: The multifaceted physical, cognitive, emotional, behavioral, and spiritual response to loss. Typical manifestations include systemic fatigue, insomnia, anxiety, cognitive confusion, guilt, and anger.
In of bereaved individuals, normal grief transitions into a chronic, debilitating condition termed complicated bereavement disorder.
Neurological Basis: Functional imaging demonstrates that grief activates subcortical structures within the limbic system—specifically regions regulating motivation, craving, emotional intensity, and addiction circuitry. Hyperactivation of these limbic structures creates persistent emotional pain and compulsive longing for the deceased, hindering psychological adaptation.
Stigma and Help-Seeking Behaviours
Conceptualization of Stigma:
Stigma refers to a mark of disgrace, disapproval, or social rejection associated with a particular characteristic or mental health condition. Stigma labels an individual as fundamentally "different," separating them from the broader community and fostering stereotyping (e.g., depicting individuals with psychiatric conditions as unstable, violent, or untreatable).
Taxonomy of Stigma:
Self-Stigma: Occurs when an individual internalizes prevailing societal prejudices and negative stereotypes regarding mental illness. The individual applies these negative biases to themselves, experiencing feelings of shame, worthlessness, diminished self-esteem, and compromised self-efficacy.
Social Stigma (Public Stigma): The collection of negative attitudes, prejudices, and overt discrimination directed toward individuals with psychological disorders by the public. Social stigma is driven by widespread misconceptions that individuals with mental illnesses are dangerous, unpredictable, or personally responsible for their illness.
Institutional Stigma: Systemic, structural, or organizational policies—enacted by governmental bodies, healthcare systems, or private entities—that intentionally or inadvertently restrict opportunities, rights, or resource allocations for people with mental health conditions. Examples include disproportionately low funding for psychiatric research and a scarcity of community mental health services relative to physical healthcare infrastructure.
Impact of Stigma on Help-Seeking and Treatment:
Self-stigma produces intense shame and fear of being labeled, causing individuals to conceal symptoms and avoid seeking professional evaluation.
Social stigma imposes interpersonal barriers, leading patients to decline available evidence-based interventions to avoid social exclusion or discrimination.
Institutional stigma severely restricts access to timely, high-quality care through underfunded services.
The combined effect of these three stigmatizing forces is that individuals with psychological disorders frequently remain untreated for years, aggravating disorder severity and causing secondary social and financial harm (such as loss of employment or financial instability).
Clinical Treatments for Psychological Disorders
Psychotherapies:
Definition: Psychological interventions that utilize structured psychological techniques to alter maladaptive cognitive patterns, emotional responses, and behaviors, enabling patients to improve mental health and adaptive functioning.
Cognitive Behavioural Therapy (CBT):
A structured, goal-oriented psychotherapy that combines verbal cognitive restructuring with behavioral modification techniques.
Mechanism: Identifies irrational, dysfunctional, or automatic negative thoughts that maintain emotional distress and replaces them with realistic, positive cognitive alternatives. CBT is frequently combined with systematic relaxation techniques.
Clinical Applications: Highly effective in treating major depressive disorder, generalized anxiety disorder, panic disorder, Post-Traumatic Stress Disorder (PTSD), and Obsessive-Compulsive Disorder (OCD).
Systematic Desensitisation:
A behavior therapy grounded in classical conditioning principles, specifically designed for treating specific phobias.
Mechanism: Utilizes counterconditioning to replace anxiety with a physiologically incompatible response (deep muscle relaxation). The patient is trained in deep muscle relaxation techniques and formulates an anxiety/exposure hierarchy. The therapist sequentially exposes the individual to phobic stimuli, progressing gradually from the least anxiety-provoking scenario to the most distressing scenario while the patient actively maintains deep muscle relaxation.
Psychodynamic Psychotherapy:
Grounded in psychoanalytic theories developed by Sigmund Freud.
Mechanism: Focuses on uncovering unconscious mental conflicts, unresolved childhood trauma, and defense mechanisms. The therapist assists the patient in gaining insight into repressed emotional experiences and feelings toward past figures or lost relationships, relieving conscious psychological distress.
Clinical Applications: Primarily utilized for major depressive disorders and chronic interpersonal difficulties.
Systemic Therapy:
An approach that shifts clinical focus away from individual internal intrapsychic conflicts to target interactional patterns and relational dynamics within groups.
Mechanism: Evaluates systemic communication, behavioral feedback loops, and problem-solving structures within functional units rather than diagnosing individual pathology.
Clinical Applications: Widely applied in family therapy, couples counseling, and organizational/workplace conflict resolution.
Pharmacotherapies:
Definition: The clinical administration of chemical agents and pharmaceutical medications to treat psychological disorders, typically employed when underlying etiology is attributed to biological or neurochemical dysfunction.
Selective Serotonin Reuptake Inhibitors (SSRIs):
Example: Zoloft (sertraline).
Mechanism: Inhibits the presynaptic reuptake transporter proteins for serotonin (), increasing synaptic concentrations of serotonin within brain pathways to alleviate depressive and anxious symptomatology.
Antipsychotic Medications:
Example: Clozapine.
Mechanism: Modulates postsynaptic dopamine receptors (particularly receptor pathways) in the brain to reduce positive psychotic symptoms, including visual/auditory hallucinations and delusions in schizophrenia (Barlow & Durand, 2011).
Pharmacological Management of Substance Abuse:
Long-term opioid dependence (e.g., heroin addiction) is managed using substitute opioid agonists such as methadone or partial agonists such as buprenorphine.
Mechanism: Administered under strict medical supervision as part of a comprehensive rehabilitation plan, these medications satisfy physiological dependence, suppress severe craving, and eliminate compulsive drug-seeking behavior (Department of Health and Human Services, Victoria, 2016).
Biomedical Interventions:
Electroconvulsive Therapy (ECT):
A somatic treatment in which controlled electrical currents are passed through the brain to induce a brief generalized seizure under general anesthesia and muscle relaxation.
* *Procedure*: Patients are fitted with a mouthguard to protect the teeth and tongue during seizure activity. Modern ECT exerts an anticonvulsant effect upon the frontal and temporal lobes, modulating neurotransmitter sensitivity and neuroplasticity.
* *Efficacy*: Studies report symptom remission rates ranging between and in treatment-resistant major depressive disorder and severe bipolar disorder (Dierckx et al., 2012; Fink & Taylor, 2007; O'Sullivan & Gilbert, 2003).
* **Psychosurgery**:
* Surgical intervention involving the precise excision, ablation, or destruction of a small, localized region of neural tissue identified as the underlying source of severe psychiatric pathology.
* *Applications*: Reserved as an extreme intervention for intractable major depression, severe anxiety disorders (such as severe OCD), and refractory schizophrenia.
* *Efficacy and Risks*: Psychosurgery carries permanent neurocognitive risks, and clinical response is variable: fewer than half () of surgical patients achieve significant symptom improvement.
Placebo Treatments and Ethical Debate:
Placebo: An inert or pharmacologically inactive substance (e.g., a sugar pill or saline injection) administered in experimental research.
Placebo Effect: A measurable reduction in clinical symptoms arising solely from a patient's psychological expectation and belief that they are receiving an active therapeutic treatment (Burton et al., 2015). While placebo responses can produce genuine symptom relief, the therapeutic gains are often smaller and more transient than those generated by validated clinical treatments.
Ethical Considerations: Placebo-controlled trial designs involve double-blind deception, presenting significant ethical challenges. True informed consent is difficult to establish when participants are unaware they may receive an inactive substance. Furthermore, allocating psychiatric patients to a placebo arm requires withholding active, proven medical treatments, exposing vulnerable individuals to symptom exacerbation or risk of self-harm.
The Eclectic Approach to Treatment:
An eclectic approach synthesizes theoretical constructs, diagnostic tools, and therapeutic techniques from multiple psychological orientations tailored to an individual patient's presentation.
Analogy: Conceptualized as crafting a customized "fruit smoothie," where the clinician selects specific